Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
Clinical trial NCT02203526 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02203526
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-14
- Primary completion
- 2026-09-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.